Terms: = Prostate cancer AND CALCB, Calcitonin AND Diagnosis
16 results:
1. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
2. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of prostate cancer cell progression in zebrafish xenograft model.
Xu W; Foster BA; Richards M; Bondioli KR; Shah G; Green CC
Int J Oncol; 2018 Jan; 52(1):252-260. PubMed ID: 29115578
[TBL] [Abstract] [Full Text] [Related]
4. 223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer.
García Cañamaque L; Rioja Parada C; García De la Peña P
Tumori; 2017 Nov; 103(Suppl. 1):e53-e55. PubMed ID: 28525684
[TBL] [Abstract] [Full Text] [Related]
5. Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.
Ramalingam S; Eisenberg A; Foo WC; Freedman J; Armstrong AJ; Moss LG; Harrison MR
Int J Urol; 2016 Dec; 23(12):1038-1041. PubMed ID: 27766686
[TBL] [Abstract] [Full Text] [Related]
6. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy.
Yee EF; White RE; Murata GH; Handanos C; Hoffman RM
J Gen Intern Med; 2007 Sep; 22(9):1305-10. PubMed ID: 17634780
[TBL] [Abstract] [Full Text] [Related]
7. cancer-treatment-induced bone loss, part 2.
Michaud LB; Goodin S
Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
[TBL] [Abstract] [Full Text] [Related]
8. cancer-treatment-induced bone loss, part 1.
Michaud LB; Goodin S
Am J Health Syst Pharm; 2006 Mar; 63(5):419-30. PubMed ID: 16484516
[TBL] [Abstract] [Full Text] [Related]
9. cancer treatment-induced bone loss in patients with breast or prostate cancer.
Maxwell C; Viale PH
Oncol Nurs Forum; 2005 May; 32(3):589-603. PubMed ID: 15897934
[TBL] [Abstract] [Full Text] [Related]
10. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer.
Deftos LJ
Prostate Suppl; 1998; 8():23-31. PubMed ID: 9690660
[TBL] [Abstract] [Full Text] [Related]
11. Serum calcitonin in small cell carcinoma of the prostate.
Sim SJ; Glassman AB; Ro JY; Lee JJ; Logothetis CJ; Liu FJ
Ann Clin Lab Sci; 1996; 26(6):487-95. PubMed ID: 8908318
[TBL] [Abstract] [Full Text] [Related]
12. Small cell carcinoma of the urinary bladder. A clinicopathological study of six cases.
Lopez JI; Angulo JC; Flores N; Toledo JD
Br J Urol; 1994 Jan; 73(1):43-9. PubMed ID: 7507782
[TBL] [Abstract] [Full Text] [Related]
13. Rectal and colonic carcinoids. A clinicopathologic study of 84 cases.
Federspiel BH; Burke AP; Sobin LH; Shekitka KM
Cancer; 1990 Jan; 65(1):135-40. PubMed ID: 2293859
[TBL] [Abstract] [Full Text] [Related]
14. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract] [Full Text] [Related]
15. Specific tumor markers in diagnostic cytology. Immunoperoxidase studies of carcinoembryonic antigen, lysozyme and other tissue antigens in effusions, washes and aspirates.
Walts AE; Said JW
Acta Cytol; 1983; 27(4):408-16. PubMed ID: 6410636
[TBL] [Abstract] [Full Text] [Related]
16. Selected applications of immunoperoxidase techniques in surgical pathology.
Espinoza CG; Pillarisetti SG; Azar HA
Ann Clin Lab Sci; 1983; 13(3):240-8. PubMed ID: 6307109
[TBL] [Abstract] [Full Text] [Related]
